Thyroid cancer - clinical
You are looking at 31 - 40 of 50 items
Search for other papers by João Roque in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Tiago Nunes Silva in
Google Scholar
PubMed
Search for other papers by Catarina Regala in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Background and objective
Lenvatinib showed promising results in a subgroup of patients with poorly differentiated thyroid carcinoma (PDTC) in the SELECT trial. Our aim was to report the effectiveness and tolerability of lenvatinib in our series of PDTC patients.
Methods
Medical records of eight consecutive patients with PDTC treated with lenvatinib in a single center between January 2019 and October 2022 were retrospectively reviewed. Inclusion criteria were PDTC diagnosis based on Turin criteria and evidence of disease progression in the previous 6 months.
Results
Eight PDTC patients received an average dose of lenvatinib of 18.1 mg for a median duration of treatment of 10.3 months. The baseline Eastern Cooperative Oncology Group performance status was ≥2 in 50% of patients. Two patients had unresectable primary tumor. Seven patients showed extrathyroidal disease, particularly mediastinal lymph nodes (85.7%), lung (71.4%), and bone (71.4%). The disease control rate was 100%, with partial response and stable disease in 12.5 and 87.5%, respectively. The median time to best overall response was 3 months, and the median duration of response was 7.5 months. Median progression-free survival was 12 months and median overall survival was not reached. At 6, 12, and 18 months, overall survival was 87.5, 71.4, and 57.1%, respectively. All patients experienced drug-related adverse effects (AEs). Four (50%) had dose reductions and two (25%) had temporary treatment interruptions. Lenvatinib was stopped in two patients due to grade ≥3 AEs.
Conclusion
Lenvatinib is an effective treatment for real-world PDTC patients. Adequate management of comorbidities and AEs increases treatment tolerability and minimizes dose reductions.
University of Lille, Lille, France
Search for other papers by Benjamin Chevalier in
Google Scholar
PubMed
Search for other papers by Oriane Karleskind in
Google Scholar
PubMed
University of Lille, Lille, France
Search for other papers by Arnaud Jannin in
Google Scholar
PubMed
Search for other papers by Olivier Farchi in
Google Scholar
PubMed
Search for other papers by Catherine Vermaut in
Google Scholar
PubMed
CRIStAL UMR CNRS 9189, University of Lille, Villeneuve-d’Ascq, France
Search for other papers by Alexandre Escande in
Google Scholar
PubMed
Search for other papers by Clio Baillet in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Stéphanie Espiard in
Google Scholar
PubMed
University of Lille, Lille, France
Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes (EGID), CHU Lille, Lille, France
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Search for other papers by Bruno Carnaille in
Google Scholar
PubMed
Department of Pathology, Lille University Hospital, Lille, France
University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
Search for other papers by Emmanuelle Leteurtre in
Google Scholar
PubMed
Search for other papers by Christine Do Cao in
Google Scholar
PubMed
Introduction
Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer with a bleak prognosis. Favorable outcomes are rare but help decipher molecular pathophysiology, investigate prognosis factors, and discover new therapeutic targets.
Case presentation
Two patients were diagnosed with locally advanced nonresectable ATC, one with metastatic extension. Each patient received chemotherapy and radiotherapy, allowing thyroid surgical resection. In both cases, the pathological examination was consistent with complete response with no viable tumor cells. After follow-ups of 48 and 70 months, both patients remain disease-free. Molecular explorations on thyroid biopsies revealed microsatellite instability (MSI) and alterations on mismatch repair–gene complex, also PTEN and ATM variants in both cases. Both also presented with non-classical immune infiltrate composed of equal parts T CD4+ lymphocytes and macrophages.
Conclusion
We report two cases of patients cured from advanced ATC and for the first time provide genetic and immunological explorations in this setting. It seems with these two cases that MSI-ATCs may indicate a better prognosis. Our study hypothesizes different responsible mechanisms including increased sensitivity to chemoradiotherapy and/or immune tumor infiltrate modulation.
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Sara Donato in
Google Scholar
PubMed
Search for other papers by Mariana Horta in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Search for other papers by Miguel Rito in
Google Scholar
PubMed
Search for other papers by Pedro Gomes in
Google Scholar
PubMed
Nova Medical School, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Background
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies for ATC are emerging due to advances in molecular profiling of these tumors. Entrectinib is a potent oral selective inhibitor of neutrotrophic tropomyosin receptor kinase (NTRK), ROS1, and anaplastic lymphoma kinase fusions. The experience regarding ATC and other thyroid carcinomas, particularly in the neoadjuvant setting, is minimal.
Case report
We present a case of a 51-year-old female patient presenting with a bulky mass of the left thyroid lobe measuring 100 × 108 × 80 mm that was considered surgically unresectable. While waiting for next-generation sequence (NGS) profiling, lenvatinib was initiated. There was an initial clinical and imagiologic response; however, progression occurred after 12 weeks, and at this time NGS identified an ETV6-NTRK3 fusion and entrectinib was started. After 12 weeks, tumor diameters reduced to a minimum of 68×60×49 mm, and the patient underwent total thyroidectomy plus central lymphadenectomy. Histological diagnosis confirmed an ATC (pT4a R2 N1a). Adjuvant radiotherapy (RT) (60 Grays) with weekly paclitaxel (45 mg/m2) was then administered followed by maintenance entrectinib 600 mg daily. Fluorodeoxyglucose positron emission tomography performed 3 months after completion of RT showed only non-specific uptake in the posterior wall of the hypopharynx and larynx, suggestive of inflammation.
Conclusion
We report the first case of an ATC with a dramatic response to neoadjuvant therapy with entrectinib, which enabled surgical resection of an ab initio unresectable tumor.
Search for other papers by Simona Censi in
Google Scholar
PubMed
Search for other papers by Jacopo Manso in
Google Scholar
PubMed
Search for other papers by Teresa Benvenuti in
Google Scholar
PubMed
Search for other papers by Ilaria Piva in
Google Scholar
PubMed
Search for other papers by Maurizio Iacobone in
Google Scholar
PubMed
Search for other papers by Alberto Mondin in
Google Scholar
PubMed
Search for other papers by Francesca Torresan in
Google Scholar
PubMed
Search for other papers by Daniela Basso in
Google Scholar
PubMed
Search for other papers by Gino Crivellari in
Google Scholar
PubMed
Search for other papers by Stefania Zovato in
Google Scholar
PubMed
Search for other papers by Caterina Mian in
Google Scholar
PubMed
Objective
Calcitonin (Ct) represents the most important biochemical marker of medullary thyroid cancer (MTC), but has certain limits. We analyzed the performance of procalcitonin (ProCt) in follow-up MTC patients.
Methods
In this monocentric and retrospective study, we consecutively obtained ProCt and Ct values from all MTC patients that we visited during the period from April 2021 to May 2022. Patients were defined as having structural evidence of disease (29/90, 32.2%) irrespective of Ct values or, in its absence, as not evident disease (NED) if Ct was ≤10 ng/L (47/90, 52.2%), or minimal residual disease if Ct was >10 ng/L (14/90, 15.6%).
Results
Ct and ProCt values were highly correlated (r = 0.883, P < 0.01). Median ProCt values differed between NED, minimal residual disease, and structural disease, being 0.04 ng/mL, 0.26 ng/mL, and 1.98 ng/mL, respectively (P < 0.01). ProCt was undetectable (<0.04 ng/mL) in 40/47 (85.1%) of NED patients, in 3/14 (21.4%) patients with minimal residual disease and in none of the patients with a structural disease (P < 0.01). Among the 11 patients with detectable but ≤10 ng/L Ct and undetectable ProCt values, none had a structural disease. The most accurate cut-off of ProCt to distinguish between the presence or absence of a structural disease was >0.12 ng/mL (P < 0.01, area under the curve: 0.963), with the following sensitivity, specificity, positive predictive value, and negative predictive value (NPV): 100%, 83.61%, 74.4%, and 100.0%.
Conclusions
ProCt and Ct have a high correlation in MTC follow-up. ProCt may be useful as an adjunct to Ct, especially for its NPV concerning the structural disease.
Search for other papers by Bernadette L Dekker in
Google Scholar
PubMed
Department of Emergency Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
Search for other papers by Anouk N A van der Horst-Schrivers in
Google Scholar
PubMed
Search for other papers by Adrienne H Brouwers in
Google Scholar
PubMed
Search for other papers by Christopher M Shuford in
Google Scholar
PubMed
Search for other papers by Ido P Kema in
Google Scholar
PubMed
Search for other papers by Anneke C Muller Kobold in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Objective
Thyroglobulin (Tg) is an established tumor marker for differentiated thyroid carcinoma (DTC) patients. However, Tg immunoassays can be subject to Tg autoantibody (TgAb) interference resulting in incorrect Tg values. Therefore, Tg measurement with liquid chromatography-tandem mass spectrometry (LC-MS/MS) could be promising in patients with TgAbs. In this study, we compared Tg IRMA and Tg-LC-MS/MS analytically in the presence of TgAbs. Furthermore, we compared the clinical interpretation of results obtained by both Tg assays in DTC patients with lower TgAbs titers (<10 U/mL) during 131I ablation therapy.
Methods
Totally 118 DTC patients diagnosed between 2006 and 2014 in a University Medical Center were followed with the Tg-IRMA (Thermo Fischer Scientific) and ARCHITECT anti-Tg (Abbott Laboratories) assays. We re-analyzed their samples with a sensitive Tg-LC-MS/MS method (Labcorp, limit of quantification of 0.02 ng/mL). Passing-Bablok regression analysis was performed on samples obtained during 131I ablation therapy and follow-up.
Results
In 304 samples with lower TgAb titers, a good analytical agreement was found between both Tg assays (slope of 1.09 (95% CI: 1.05–1.16)). Fifty-five samples with potentially interfering TgAbs showed higher Tg-LC-MS/MS values than Tg-IRMA (slope of 1.45 (95% CI: 1.12–>>100)). In patients(n = 91) with lower TgAb titers at the time of 131I ablation therapy, the Tg assays showed a clinical concordance of 91.2, 87.9, and 98.9%, respectively, using a Tg cut-off value of 1.0, 2.0, and 5.0 ng/mL.
Conclusions
In DTC patients with lower titer TgAbs, Tg-IRMA is still a reliable and useful tumor marker. In DTC patients with potentially interfering TgAbs, Tg-IRMA values decreased due to TgAb interference.
Search for other papers by Marine Sitbon in
Google Scholar
PubMed
Search for other papers by Porhuoy Chou in
Google Scholar
PubMed
Search for other papers by Seydou Bengaly in
Google Scholar
PubMed
Search for other papers by Brigitte Poirot in
Google Scholar
PubMed
Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed
Search for other papers by Laure Deville in
Google Scholar
PubMed
Search for other papers by Atanas Pachev in
Google Scholar
PubMed
Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed
Search for other papers by Clement Dumont in
Google Scholar
PubMed
Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed
The endocrine secretions of carcinomas can be life-threatening. Medullary thyroid carcinoma (MTC) is a rare cancer that is often associated with cortisol secretion, leading to paraneoplastic Cushing’s syndrome. Mutations of the proto-oncogene RET are driver molecular events in 70% of MTC cases. Here, we report a case of a woman, born in 1956, who was diagnosed with sporadic MTC in 2005, with subsequent relapses treated with focal treatments. In April 2019, she presented with severe and rapidly progressive paraneoplastic Cushing’s syndrome associated with lymph node, lung, liver and bone metastases. A supraclavicular lymph node biopsy revealed a somatic p.M918T (c.2753T>C) mutation in exon 16 of the RET proto-oncogene. The patient began treatment with selpercatinib in September 2019. Clinical efficacy was immediate. Chronic diarrhea disappeared within a few days. Clinical hypercorticism quickly disappeared, with quick improvements in muscle and skin conditions and fatigue. Two months after treatment initiation, urinary free cortisol normalized to 42 µg/24 h. Levels of the tumor markers carcinoembryonic antigen (CEA) and calcitonin also greatly decreased from baseline. After 34 months of treatment, selpercatinib elicits sustained clinical, biological and morphological responses. In summary, this case report illustrates the rapid and long-lasting antisecretory effect of selpercatinib associated with tumor control. As Cushing’s syndrome associated with medullary thyroid cancer is associated with poor prognosis, this case report is very encouraging. In addition, this suggests the potential benefit of molecular testing in all cases of medullary thyroid cancer.
Search for other papers by Luciana Puleo in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Irene Bargellini in
Google Scholar
PubMed
Search for other papers by Giuseppe Boni in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Claudio Traino in
Google Scholar
PubMed
Search for other papers by Tommaso Depalo in
Google Scholar
PubMed
Search for other papers by Giulia Lorenzoni in
Google Scholar
PubMed
Search for other papers by Francesca Bianchi in
Google Scholar
PubMed
Search for other papers by Duccio Volterrani in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Search for other papers by Maurizia Rossana Brunetto in
Google Scholar
PubMed
Search for other papers by Barbara Coco in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Objectives
Liver metastases occur in 45% of patients with advanced metastatic medullary thyroid cancer (MTC). Transarterial radioembolization (TARE) has been proposed to treat liver metastases (LM), especially in neuroendocrine tumors. The aim of this study was to investigate the biochemical (calcitonin and carcino-embryonic antigen) and objective response of liver metastases from MTC to TARE.
Methods
TARE is an internal radiotherapy in which microspheres loaded with β-emitting yttrium-90 (90Y) are delivered into the hepatic arteries that supply blood to LM. Eight patients with progressive multiple LM underwent TARE and were followed prospectively. They were clinically, biochemically and radiologically evaluated at 1, 4, 12 and 18 months after TARE.
Results
Two patients were excluded from the analysis due to severe liver injury and death due to extrahepatic disease progression, respectively. One month after TARE, a statistically significant (P = 0.02) reduction of calcitonin was observed in all patients and remained clinically relevant during follow-up; reduction of CEA, although not significant, was found in all patients. Significant reduction of liver tumor mass was observed 1, 4 and 12 months after TARE (P = 0.007, P = 0.004, P = 0.002, respectively). After 1 month, three of six patients showed partial response (PR) and three of six stable disease (SD) according to RECIST 1.1, while five of six patients had a PR and one of six a SD according to mRECIST. The clinical response remained relevant 18 months after TARE. Excluding one patient, all others showed only a slight and transient increase in liver enzymes.
Conclusions
TARE is effective in LM treatment of MTC. The absence of severe complications and the good tolerability make TARE a valid therapeutic strategy when liver LM are multiple and progressive.
Search for other papers by Juan Antonio Vallejo Casas in
Google Scholar
PubMed
Search for other papers by Marcel Sambo in
Google Scholar
PubMed
Search for other papers by Carlos López López in
Google Scholar
PubMed
Search for other papers by Manuel Durán-Poveda in
Google Scholar
PubMed
Search for other papers by Julio Rodríguez-Villanueva García in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Search for other papers by Marta Llanos in
Google Scholar
PubMed
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
Search for other papers by Javier Aller in
Google Scholar
PubMed
Search for other papers by Virginia Pubul in
Google Scholar
PubMed
Search for other papers by Sonsoles Guadalix in
Google Scholar
PubMed
Search for other papers by Guillermo Crespo in
Google Scholar
PubMed
Search for other papers by Cintia González in
Google Scholar
PubMed
Search for other papers by Carles Zafón in
Google Scholar
PubMed
Search for other papers by Miguel Navarro in
Google Scholar
PubMed
Search for other papers by Javier Santamaría-Sandi in
Google Scholar
PubMed
Search for other papers by Ángel Segura in
Google Scholar
PubMed
Search for other papers by Pablo Gajate in
Google Scholar
PubMed
Search for other papers by Marcelino Gómez-Balaguer in
Google Scholar
PubMed
Search for other papers by Javier Valdivia in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
Search for other papers by Juan Carlos Galofré in
Google Scholar
PubMed
Search for other papers by Beatriz Castelo in
Google Scholar
PubMed
Search for other papers by María José Villanueva in
Google Scholar
PubMed
Search for other papers by Iñaki Argüelles in
Google Scholar
PubMed
Search for other papers by Lorenzo Orcajo-Rincón in
Google Scholar
PubMed
Background
Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS).
Objective
The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal.
Methods
A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated.
Results
Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3–15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7–16.2) years; log-rank test P = 0.4737). Age at diagnosis being <55 years was associated with a lower risk of death (Wald chi-square (Wc-s) P < 0.0001), while a poor response to RAI to a higher risk of death ((Wc-s) P < 0.05). In the eDTC cohort, median (RP)FS (95% CI) was of 1.7 (1.0–2.0) years after RAI, with R0/R1 surgeries being the only common significant favourable factor for longer (RP)FS and time to aDTC ((Wc-s) P < 0.05).
Conclusion
Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.
College of Medicine, Yonsei University, Seoul, Republic of Korea
Search for other papers by Jihwan Yoo in
Google Scholar
PubMed
Search for other papers by Hee Jun Kim in
Google Scholar
PubMed
Search for other papers by Seok Mo Kim in
Google Scholar
PubMed
Search for other papers by Hun Ho Park in
Google Scholar
PubMed
Introduction
Brain metastasis in differentiated thyroid cancer (DTC) is rare (frequency < 1%) and has a poor prognosis. Treatment strategies for brain metastasis are not well established.
Objectives
We conducted a retrospective analysis to identify predictive factors for patient outcomes and verify surgical indications for patients with brain metastasis and DTC.
Methods
The study included 34 patients with pathologically confirmed DTC with brain metastasis from March 2008 to November 2020. The associations between overall survival (OS) and clinical factors were evaluated. Cox regression analysis was used to determine the relationship between clinical factors and OS. To assess the survival benefit of craniotomy, Kaplan–Meier survival analysis was performed for each variable whose statistical significance was determined by Cox regression analysis.
Results
The median OS of the entire patient sample was 11.4 months. Survival was affected by the presence of lung metastasis (P = 0.033) and the number of brain metastases (n > 3) (P = 0.039). Only the subgroup with the number of brain metastases ≤3 showed statistical significance in the subgroup analysis of survival benefit following craniotomy (P = 0.048).
Conclusions
The number of brain metastases and the existence of lung metastasis were regarded more essential than other clinical factors in patients with DTC in this study. Furthermore, craniotomies indicated a survival benefit only when the number of brain metastases was ≤3. This finding could be beneficial in determining surgical indications in thyroid cancer with brain metastasis.
Search for other papers by Diana Borges Duarte in
Google Scholar
PubMed
Search for other papers by Vânia Benido Silva in
Google Scholar
PubMed
Search for other papers by Guilherme Assunção in
Google Scholar
PubMed
Search for other papers by André Couto Carvalho in
Google Scholar
PubMed
Search for other papers by Cláudia Freitas in
Google Scholar
PubMed
Introduction
The occurrence of non-thyroidal second primary malignancy (NTSPM) in patients with papillary thyroid cancer (PTC) is well documented, but epidemiological data are conflicting.
Objective
The aim of this study was to evaluate the incidence of NTSPM in a large series of patients with PTC and to assess its potential risk factors.
Methods
Single-center cohort study with retrospective data collection conducted on consecutive PTC patients diagnosed from 1988 to 2018 with a minimum follow-up time of 2 years. NTSPM was defined as any primary malignancy with histological confirmation occurring in an anatomical site other than the thyroid. According to the timing of occurrence, NTSPM were subdivided into anachronous, synchronous or metachronous (diagnosed >6 months before, within 6 months and >6 months after PTC diagnosis, respectively).
Results
We included 773 individuals (83.3% females), median age at PTC diagnosis was 47.0 (IQR: 37.0–58.0) years and median follow-up time was 9.9 (6.2–16.3) years. Incidence of NTSPM was 15.5% (n = 120) and its standard incidence ratio (SIR) was higher when compared to the general population (SIR: 2.70). Family history of malignancy and younger age at diagnosis were associated respectively with 206 and 4% increased risk of developing metachronous neoplasia (HR: 2.06 (95% CI: 1.10–3.86) and 1.04 (95% CI: 1.02–1.05), respectively).
Conclusion
In our series, the occurrence of NTSPM was not uncommon and its incidence was higher compared to the general population. First-degree family history of malignancy was a strong risk factor for multiple primary malignancies.
